arsenic trioxide has been researched along with Cancer of Ovary in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, S; Tchounwou, PB | 1 |
| Lu, W; Shen, Y; Shen, Z; Tang, S; Wei, X; Xu, J | 1 |
| Anur, P; Kodigepalli, KM; Nanjundan, M; Sims, PJ; Spellman, P | 1 |
| Chakraborty, S; Pradhan, AK; Singh, S | 1 |
| Di, W; Ding, CW; Hong, ZB; McGowan, E; Shi, J; Wu, ZM; Xia, P; Zhang, N | 1 |
| Arora, N; Das, R; Malhotra, P; Nath, A; Patel, FD; Varma, N; Varma, S | 1 |
| Haller, E; Mills, GB; Nanjundan, M; Patel, S; Raffoul, F; Smith, DM | 1 |
| Campla, C; Nanjundan, M; Raffoul, F | 1 |
| Chan, SY; Ho, PC; Ong, PS | 2 |
| Nie, C; Qiu, J; Wang, F; Wei, Y; Yuan, Z; Zhao, X; Zhao, Z | 1 |
| Bhuta, S; Ding, B; Huang, J; Liu, N; Sun, Y; Tai, S; Thor, RK | 1 |
| Bauckman, KA; Dutta, PS; Kodigepalli, KM; Nanjundan, M | 1 |
| Huang, S; Jiang, S; Kong, B; Ma, Y | 1 |
| Huang, SG; Jiang, S; Kong, BH; Yang, RF | 1 |
| Huang, SG; Jiang, S; Kong, BH; Ma, YY | 1 |
| Bornstein, J; Fares, F; Haj, A; Harroch, J; Sagi, S | 1 |
| Wang, B; Zhang, J | 1 |
| Goker, E; Karabulut, B; Omay, SB; Sanli, UA; Sezgin, C; Terzioglu, E; Uslu, R | 1 |
| Du, YH; Ho, PC | 1 |
20 other study(ies) available for arsenic trioxide and Cancer of Ovary
| Article | Year |
|---|---|
p53 as a unique target of action of cisplatin in acute leukaemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cisplatin; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Ovarian Neoplasms; Tumor Suppressor Protein p53 | 2022 |
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.
Topics: Adenosine Diphosphate; AMP-Activated Protein Kinases; Animals; Apoptosis; Arsenic Trioxide; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Ferroptosis; Humans; Mice; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Ribose; Stearoyl-CoA Desaturase | 2022 |
Phospholipid Scramblase 1, an interferon-regulated gene located at 3q23, is regulated by SnoN/SkiL in ovarian cancer cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Chromosomes, Human, Pair 3; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Ovarian Neoplasms; Oxides; Phospholipid Transfer Proteins; Proto-Oncogene Proteins; RNA Interference; RNA, Messenger | 2013 |
SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Blotting, Western; Chromatin Immunoprecipitation; DNA-Binding Proteins; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Immunoprecipitation; MDS1 and EVI1 Complex Locus Protein; Mutagenesis, Site-Directed; Ovarian Neoplasms; Oxides; Proto-Oncogene Mas; Proto-Oncogenes; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; SUMO-1 Protein; Sumoylation; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured | 2013 |
Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cisplatin; Drug Synergism; Female; Gene Expression Profiling; Humans; Ovarian Neoplasms; Oxides | 2009 |
Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Choriocarcinoma; Female; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neuroectodermal Tumors; Ovarian Neoplasms; Oxides; Prognosis; Tretinoin | 2010 |
Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.
Topics: Acetylcysteine; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Beclin-1; Carcinoma; Cell Line, Tumor; Female; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Microtubule-Associated Proteins; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta; Ubiquitin-Activating Enzymes | 2010 |
SnoN/SkiL, a TGFβ signaling mediator: a participant in autophagy induced by arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Female; Humans; Intracellular Signaling Peptides and Proteins; Ovarian Neoplasms; Oxides; Proto-Oncogene Proteins; Reactive Oxygen Species; Signal Transduction; Transforming Growth Factor beta | 2010 |
Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Fibroblasts; Glutathione; Glutathione Peroxidase; Humans; Intracellular Space; Ovarian Neoplasms; Oxidative Stress; Oxides | 2011 |
BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; Cell Line, Tumor; Cell Survival; Cisplatin; Electrophoresis, Polyacrylamide Gel; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Silencing; Humans; Immunoblotting; Membrane Proteins; Ovarian Neoplasms; Oxides; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA, Small Interfering | 2011 |
Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Humans; Interleukin-1alpha; NF-E2-Related Factor 2; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Oxides; Paclitaxel | 2012 |
Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Caspase 3; Caspase 7; Cell Cycle Proteins; Cell Line, Tumor; Drug Synergism; Everolimus; Female; Humans; Immunosuppressive Agents; Mice; Mice, SCID; Ovarian Neoplasms; Oxides; Phosphoproteins; Proto-Oncogene Proteins c-akt; Sirolimus; Xenograft Model Antitumor Assays | 2012 |
SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Ovarian Neoplasms; Oxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA Interference; Shc Signaling Adaptor Proteins; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; src-Family Kinases | 2013 |
[Apoptosis of drug-resistant human ovarian carcinoma cell line 3AO/cDDP induced by arsenic trioxide and its mechanism].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Drug Resistance, Neoplasm; Fas Ligand Protein; fas Receptor; Female; Humans; Membrane Glycoproteins; Ovarian Neoplasms; Oxides; Tumor Cells, Cultured | 2002 |
[Primary study of arsenic trioxide inhibits abdomino-metastatic tumor formation of human ovarian carcinoma in nude mice and its mechanisms].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Fas Ligand Protein; fas Receptor; Female; Humans; Membrane Glycoproteins; Mice; Mice, Nude; Monomeric GTP-Binding Proteins; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Ovarian Neoplasms; Oxides; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
[Impact of arsenic trioxide on proliferation and metastasis of drug-resistant human ovarian carcinoma cell line].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fas Receptor; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Microscopy, Electron; Monomeric GTP-Binding Proteins; Neoplasm Metastasis; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Ovarian Neoplasms; Oxides; Proteins; Proto-Oncogene Proteins c-myc; Repressor Proteins; Time Factors; Trans-Activators; Transcription Factors; Tumor Cells, Cultured | 2002 |
Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Oxides | 2005 |
Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Female; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Ovarian Neoplasms; Oxides; Peritoneal Neoplasms; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2006 |
Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Butylated Hydroxyanisole; Carcinogens; Cisplatin; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Flow Cytometry; Humans; Male; Ovarian Neoplasms; Oxides; Prostatic Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2000 |
Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Size; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Ovarian Neoplasms; Oxides; Sulfides; Time Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |